2020 ASCO Election
Voting is now open for the 2020 ASCO Election.
ASCO encourages all eligible ASCO members – those in good standing who were, as of Wednesday, October 16, 2019, (1) Full members ; (2) Emeritus members who used to be Full members or (3) Honorary members – to cast their proxy ballot to choose seven new Society leaders.
Voting will close on Monday, December 2, 2019, at 11:59 PM US Eastern Standard Time. All proxy ballots must be received by this time.
Special Meeting Notice: The proxy ballots will be delivered to the ASCO Chair of the Board (or her designee) for official casting at a special meeting to be held on Thursday, December 5, 2019, from 9:30 to 10:00 AM US Eastern Standard Time at ASCO Headquarters at 2318 Mill Road, Suite 800, Alexandria, VA 22314. This notice is issued at the direction of the Board of Directors of the American Society of Clinical Oncology.
Candidates in the 2020 ASCO Election
Learn more about ASCO's future leaders by reading their biographies. Use the links provided to navigate the candidate information.
President-Elect Candidates (One seat, 4-year term)
Dr. Loehrer is a medical oncologist specializing in cancers of the testis, bladder, colon, pancreas, and thymus gland. He is director of the Indiana University Melvin and Bren Simon Cancer Center, an IU Distinguished Professor, H.H. Gregg Professor of Oncology, and associate dean for cancer research at Indiana University School of Medicine. Dr. Loehrer is a past member and/or chair of numerous ASCO committees, including the Cancer Communications Committee, Career Development Committee, Professional Development Committee, Annual Meeting Education Committee, Leadership Development Program and served as a member of the ASCO Board of Directors from 1998-2001. In 2017, Dr. Loehrer received the inaugural Allen S. Lichter Visionary Leader Award from ASCO for his extraordinary leadership.
Dr. Vokes specializes in head and neck and lung cancers. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance ( formerly Cancer and Leukemia Group B ) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, and a member of the Conquer Cancer Development and Fundraising Committee, and the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.
Board of Directors: Designated International Oncologist Candidates (One seat, 4-year term)
Dr. Albers is a surgical oncologist, professor, and chair of the Department of Urology at Heinrich-Heine University Düsseldorf. He served on the ASCO Annual Meeting Scientific Program Committee from 2013 to 2016 as a member of the Genitourinary Cancer track.
Dr. Soto is a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. He currently serves on several ASCO committees, including the Annual Meeting Scientific Program Committee, Journal of Global Oncology Editorial Board, Social Media Working Group, Conquer Cancer Grants Selection Committee, Diversity and Inclusivity Task Force, Technology Research Group, and Publishing Research Group. He received a 2019 Conquer Cancer Career Development Award. Previously, Dr. Soto has served on several other ASCO research groups and advisory panels, contributed to the ASCO Connection and ASCO Daily News, and was selected for a Journal of Global Oncology Editorial Fellowship.
Board of Directors: Designated Pediatric Oncologist Candidates (one seat, 4-year term)
Dr. Gore is a pediatric oncologist, professor, and chief of Pediatric Hematology, Oncology and Bone Marrow Transplantation at the University of Colorado School of Medicine. She is also the Ergen Family Chair in pediatric cancer at Children’s Hospital Colorado and the co-director of the Developmental Therapeutics Program at the University of Colorado Cancer Center. She currently volunteers on the Cancer Research Committee and is a past member of multiple ASCO committees, such as the Broadening Eligibility Criteria Implementation Task Force and the Annual Meeting Scientific Program Committee.
Dr. Henderson is an associate professor of pediatrics, director of the Childhood Cancer Survivor Center at the University of Chicago, and director of survivorship for the University of Chicago Comprehensive Cancer Center. She is a graduate of the 2018 President Leadership Scholars program and a 2015 graduate of the ASCO Leadership Development Program. Dr. Henderson is the chair of the ASCO Adolescent and Young Adult (AYA) Survivorship Work Group and a member of several ASCO committees, including the Government Relations Committee, the Survivorship Guideline Advisory Group, and Osteoporosis in Survivors of Adult Cancers Expert Panel. She is the past chair of the Cancer Survivorship Committee and a past member of multiple ASCO committees, such as the Conquer Cancer Grants Selection Committee.
Board of Directors: Undesignated Specialty Candidates (Two seats, each a 4-year term)
Dr. Carey is Chief of Hematology/Oncology, Associate Director of Clinical Sciences, and the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at the University of North Carolina Lineberger Comprehensive Cancer Center. She is also Physician-In-Chief of the N.C. Cancer Hospital. Dr. Carey is a member of ASCO’s Breast Cancer Guideline Advisory Group. She previously served the Society as chair of the Nominating Committee, chair of the Professional Development Committee, track leader of the Annual Meeting Education Committee, and a member of the Journal of Clinical Oncology editorial board.
Dr. Page is a medical oncologist, hematologist, president, and director of research at The Center for Cancer and Blood Disorders in Fort Worth and in Weatherford, TX. He currently serves as an ASCO representative to the American Medical Association House of Delegates. He also serves as the clinical director for both ASCO CancerLinQ and ASCO Quality Oncology Practice Initiative (QOPI). Dr. Page is the immediate past chair of ASCO’s Clinical Practice Committee. He is a past chair of ASCO’s State Affiliate Council and is currently the Texas Representative. He previously served on ASCO’s Nominating Committee as the community oncology representative, and on ASCO’s Government Relations Committee. In 2017, Dr. Page received the ASCO Advocate of the Year Award.
Dr. Plimack serves as chief of the division of genitourinary medical oncology at Fox Chase Cancer Center in Philadelphia. She is a professor of medical oncology and the director of genitourinary clinical research at the center. She is a past member and track chair of the ASCO Scientific Program Committee, Genitourinary (Non-Prostate) Cancer track. Dr. Plimack received a Conquer Cancer Merit Award at the 2008 Genitourinary Cancers Symposium.
Dr. Tap is Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, where he leads the clinical, basic science, and translational aspects of the Sarcoma Medical Oncology Program. He is an Associate Member at Memorial Sloan Kettering Cancer Center and an Associate Professor of Medicine at Weill Cornell Medical College. Dr. Tap is a track leader on ASCO’s Annual Meeting Education Committee and a member of both the Broadening Clinical Trial Eligibility Criteria Task Force and TAPUR Steering Group. He recently served as the 2018-2019 chair of the ASCO Health Equity Committee and from 2012-2017 served as the chair of the ASCO/Health Volunteers Overseas Oncology Steering Committee.
Nominating Committee: Undesignated Specialty Candidates (Two seats, each a 3-year term)
Dr. Berlin is a medical oncologist specializing in gastrointestinal cancers and investigational drug development. He is associate director for clinical research, an Ingram professor of cancer research, and a professor of medicine (hematology/oncology) at Vanderbilt-Ingram Cancer Center. He is a past member of numerous ASCO committees, including the Scientific Program Committee, Cancer Education Committee, and Ethics Committee. Additionally, Dr. Berlin served as program chair for the 2008 Gastrointestinal Cancers Symposium, chair of the Gastrointestinal Non-Colorectral Education Subcommittee, and co-chair of the Clinically Meaningful Outcomes in Pancreatic Cancer Subcommittee and currently serves on two ASCO guidelines committees. He has served as an ad hoc reviewer for the Journal of Clinical Oncology and has authored or coauthored more than a dozen articles for that publication.
Dr. McLeod is the medical director of the DeBartolo Family Personalized Medicine Institute, a senior member in the Division of Population Sciences, and chair of the Department of Individualized Cancer Management at Moffitt Cancer Center in Tampa, Florida. He is also a State of Florida Endowed Chair and a professor at the University of South Florida Colleges of Medicine & Pharmacy. Dr. McLeod is an associate editor for JCO Precision Oncology and a member of ASCO’s Taxonomy Committee. He is a subcommittee chair for ASCO’s Targeted Agent and Profiling Utilization Registration (TAPUR) Study Molecular Tumor Board and has previously served on several ASCO Committees, including the Education and Scientific Program Committees.
Dr. Mitchell is a hematologist and oncologist currently serving as director emeritus and senior advisor and the George E. Becker Professor of Medicine at the Stanford Cancer Institute. She has held the roles of treasurer, vice president, and president at the American Society of Hematology (ASH), as co-leader of the ASH Clinical Research Training Institute, and as vice chair of the Leukemia & Lymphoma Society. Dr. Mitchell has been a member of several advisory boards, including a National Cancer Institute Board of Scientific Counselors, and has served on the editorial board of more than six journals.
Dr. Zuckerman is the executive medical director of St. Luke’s Mountain States Tumor Institute (MSTI) in Boise, Idaho. He is also president of the Idaho Society of Clinical Oncology. Dr. Zuckerman is a past chair of ASCO’s Clinical Practice Committee and has previously served on ASCO’s Quality of Care Council, Oncology Training Programs Committee, and other workgroups and expert panels.
View Candidate Disclosures for the 2020 ASCO election candidates, current as of October 17, 2019.
If you have any questions about the 2020 ASCO election, please contact firstname.lastname@example.org or 571-483-1316.
For best viewing and voting experience, please make sure you are using an internet browser other than Safari to view this site.